Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert J Ossenkoppele

Showing results (161-170 of 193) with videos related to

Pageof 20
Sort By:
The New England Journal of Medicine|March 31, 2018
Molecular Minimal Residual Disease in Acute Myeloid LeukemiaMojca Jongen-Lavrencic, Tim Grob, Diana Hanekamp, et al.
Blood|April 20, 2018
RNA-based <i>FLT3</i>-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AMLDavid G J Cucchi, Barbara Denys, Gertjan J L Kaspers, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
Annals of Hematology|April 11, 2013
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study groupNoortje Thielen, Bronno van der Holt, Gregor E G Verhoef, et al.
Genes, Chromosomes & Cancer|February 26, 2017
Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trialMarian J Stevens-Kroef, Daniel Olde Weghuis, Najat ElIdrissi-Zaynoun, et al.
Blood|February 2, 2022
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndromeTim Grob, Adil S A Al Hinai, Mathijs A Sanders, et al.
European Journal of Haematology|May 30, 2021
Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patientsLok Lam Ngai, Connie Y Ma, Orla Maguire, et al.
Cell Reports|December 13, 2018
IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal HematopoiesisHan J M P Verhagen, Noortje van Gils, Tania Martiañez, et al.
Blood|January 4, 2008
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemiaWendy Deenik, Bronno van der Holt, Gregor E G Verhoef, et al.
Haematologica|December 18, 2009
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemiaWendy Deenik, Jeroen J W M Janssen, Bronno van der Holt, et al.
Pageof 20

Showing results (161-170 of 193) with videos related to

Sort By:
Pageof 20
The New England Journal of Medicine|March 31, 2018
Molecular Minimal Residual Disease in Acute Myeloid LeukemiaMojca Jongen-Lavrencic, Tim Grob, Diana Hanekamp, et al.
Blood|April 20, 2018
RNA-based <i>FLT3</i>-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AMLDavid G J Cucchi, Barbara Denys, Gertjan J L Kaspers, et al.
British Journal of Haematology|April 3, 2020
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre settingDiana Hanekamp, Alexander N Snel, Angèle Kelder, et al.
Annals of Hematology|April 11, 2013
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study groupNoortje Thielen, Bronno van der Holt, Gregor E G Verhoef, et al.
Genes, Chromosomes & Cancer|February 26, 2017
Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trialMarian J Stevens-Kroef, Daniel Olde Weghuis, Najat ElIdrissi-Zaynoun, et al.
Blood|February 2, 2022
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndromeTim Grob, Adil S A Al Hinai, Mathijs A Sanders, et al.
European Journal of Haematology|May 30, 2021
Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patientsLok Lam Ngai, Connie Y Ma, Orla Maguire, et al.
Cell Reports|December 13, 2018
IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal HematopoiesisHan J M P Verhagen, Noortje van Gils, Tania Martiañez, et al.
Blood|January 4, 2008
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemiaWendy Deenik, Bronno van der Holt, Gregor E G Verhoef, et al.
Haematologica|December 18, 2009
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemiaWendy Deenik, Jeroen J W M Janssen, Bronno van der Holt, et al.
Pageof 20